Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program Cell Type
Functionality
Target(s) Indication(s) Research PreClin Phase 1 Phase 2 Phase 3
iPSC-derived Cell Products
FT576 iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
BCMA, CD38 MM ± CD38 mAb

 

FT819 iT
CAR-19, TCR-KO
CD19 Hematology

 

iPSC-derived Cell Products – Cancer Immunotherapy Collaborations
FT825/Ono iNK,iT HER2; undisclosed 2 tumor targets

 

iPSC-DERIVED CELL PRODUCTS

Program Indication Phase
FT500
iNK
Non-engineered
Solid tumors + CPI 1
BCL + CD20 mAb 1
Solid tumors + PD-L1 mAb 1
MM + CD38 mAb 1
Solid Tumors + mAb 1
FT576
iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
MM ± CD38 mAb 1
FT819
iT
CAR-19, TCR-KO
Hematology 1

iPSC-DERIVED CELL PRODUCTS – CANCER IMMUNOTHERAPY COLLABORATIONS

Program Indication Phase
Ono Pharma
iNK/iT
2 tumor targets Preclinical

iPSC = induced pluripotent stem cell iNK = iPSC-derived NK Cell iT = iPSC-derived T cell mAb = monoclonal antibody hnCD16 = high affinity, non-cleavable CD16 Fc receptor IL15-RF = IL15 receptor fusion CD38-KO = CD38 knock-out CAR = chimeric antigen receptor TCR-KO = T-cell receptor knock-out BCL = B-cell lymphoma MM = Multiple myeloma